Literature DB >> 30608206

Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors.

I Cavazzana1, S Piantoni1,2, E Sciatti3, M Fredi1,2, M Taraborelli4, I Bonadei3, P Airò1, M Metra3, A Tincani1,2, F Franceschini1,2, E Vizzardi3.   

Abstract

OBJECTIVE: The objective of this paper is to analyse whether digital capillary morphology, analysed by nailfold videocapillaroscopy (NVC), and the number of circulating CD3 + CD31 + CXCR4 + lymphocytes (angiogenic T cells) could be markers of endothelial dysfunction (ED) in systemic lupus erythematosus (SLE) without cardiovascular disease (CVD) and CV risk factors.
METHODS: Nineteen consecutive SLE patients, according to Systemic Lupus International Collaborating Clinics Classification Criteria, with a disease duration less than five years, low disease activity, without CVD and CV risk factors (diabetes, chronic renal disease, uncontrolled systemic arterial hypertension, smoking, hypercholesterolemia, obesity), statin or beta-blocker use were enrolled. Each patient and sex- and age-matched healthy control (HC) underwent Doppler echocardiogram, an endothelial function study by peripheral arterial tonometry technique, NVC and peripheral blood immunophenotyping.
RESULTS: SLE ED+ more frequently showed NVC abnormalities compared with HCs ( p < 0.0001) in terms of minor alterations ( p = 0.017), lower capillary numbers ( p = 0.0035) and major alterations. SLE ED + showed a higher rate of CD3 + CD31 + CXCR4 + lymphocytes compared with SLE ED- and with HCs. NVC + SLE showed a significantly reduced rate of total CD3 + cells, but a higher rate and absolute number of CD3 + CD31 + CXCR4 + , compared with NVC- SLE.
CONCLUSION: NVC alterations are frequent in SLE without any CV risk factors and CVD. They are associated with ED and increased circulating CD3 + CD31 + CXCR4 + lymphocytes. These findings demonstrate a clear microvascular perturbation in patients with short disease duration, low disease activity and no CV risk factors.

Entities:  

Keywords:  Anti-DNA antibodies; cardiovascular disease; systemic lupus erythematosus

Mesh:

Substances:

Year:  2019        PMID: 30608206     DOI: 10.1177/0961203318821161

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  5 in total

1.  Changes of NADH Fluorescence from the Skin of Patients with Systemic Lupus Erythematosus.

Authors:  Jaroslaw Bogaczewicz; Kamila Tokarska; Anna Wozniacka
Journal:  Biomed Res Int       Date:  2019-12-24       Impact factor: 3.411

Review 2.  Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I.

Authors:  Raquel Vieira; Selma B Souto; Elena Sánchez-López; Ana López Machado; Patricia Severino; Sajan Jose; Antonello Santini; Ana Fortuna; Maria Luisa García; Amelia M Silva; Eliana B Souto
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-10

Review 3.  IFN-I Mediates Dysfunction of Endothelial Progenitor Cells in Atherosclerosis of Systemic Lupus Erythematosus.

Authors:  Xuewei Ding; Wei Xiang; Xiaojie He
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

Review 4.  Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases.

Authors:  Liala Moschetti; Silvia Piantoni; Enrico Vizzardi; Edoardo Sciatti; Mauro Riccardi; Franco Franceschini; Ilaria Cavazzana
Journal:  Front Med (Lausanne)       Date:  2022-04-08

5.  The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus.

Authors:  Alessandra Bortoluzzi; Cecilia Beatrice Chighizola; Micaela Fredi; Elena Raschi; Caterina Bodio; Daniela Privitera; Arianna Gonelli; Ettore Silvagni; Marcello Govoni; Ilaria Cavazzana; Paolo Airò; Pier Luigi Meroni; Angela Tincani; Franco Franceschini; Silvia Piantoni; Fabio Casciano
Journal:  Front Immunol       Date:  2020-10-29       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.